There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.
New research has shown that the blood vessels that feed aggressive brain tumors have receptors that could allow a new type of drug-containing nanoparticle to be used to starve the tumors of the energy they use to grow and spread, and also cause other disruptions to their adapted existence, even killing themselves.
New research pinpoints a key cause of metastasis from an aggressive form of brain cancer in children and provides a potential new therapy for treating these tumors in the future.
Brain tumors are notoriously hard to treat. One reason is the challenge posed by the blood-brain barrier, a network of blood vessels and tissue with closely spaced cells.
Researchers from the UCL Cancer Institute have provided important molecular understanding of how injury may contribute to the development of a relatively rare but often aggressive form of brain tumor called a glioma.
Patients with glioblastoma-;the deadliest type of primary brain tumor-;may potentially benefit from immunotherapy medications called immune checkpoint inhibitors that stimulate an immune response against cancer cells.
Researchers at the University of Waterloo have created a computational model to predict the growth of deadly brain tumors more accurately.
A group of Northwestern University researchers has created a novel gene editing platform that might influence the future application of a nearly infinite library of CRISPR-based therapeutics.
A discovery regarding how a particular protein is triggered in tumor cells, conducted by researchers at the University of California, Irvine, may lead to more effective therapies for some of the deadliest types of cancer.
Cancer cells can be drawn to certain mechanical “sweet spot” conditions, according to a global team of researchers headed by University of Minnesota Twin Cities engineers.
A new cause of severe childhood brain cancer has been discovered by scientists.
Years of toil in the laboratory have revealed how a marine bacterium makes a potent anti-cancer molecule.
Researchers from the University of California San Francisco discovered two functional archetypes of metastatic cells spanning seven different types of brain cancers.
For decades, a small group of cutting-edge medical researchers have been studying a biochemical, DNA tagging system, which switches genes on or off. Many have studied it in bacteria and now some have seen signs of it in, plants, flies, and even human brain tumors.
In this interview, we speak to Roy Smythe, CEO of SomaLogic, about their groundbreaking proteomics technology that can simultaneously measure 7,000 proteins.
Unlocking the genetic mysteries behind pediatric brain tumors is at the heart of the mission of the Center for Data Driven Discovery in Biomedicine (D3b) at Children's Hospital of Philadelphia.
A team led by researchers at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School, Massachusetts General Hospital and the Broad Institute of MIT and Harvard has profiled in unprecedented detail thousands of individual cells sampled from patients' brain tumors.
Cells produce exosomes, the nano-sized biological capsules, to protect and courier delicate molecules across the body. The capsules are hard enough to resist enzymatic breakdown and acidic and temperature fluctuations in the bloodstream and gut, which makes them a major candidate for drug delivery.
Researchers have developed a new method that offers novel insights into cancer biology by enabling them to unravel how single cells absorb fatty acids.
A promising treatment for melanoma and other types of cancers is neoadjuvant immune checkpoint blockade (ICB).
A new study coordinated by the University of Trento could have identified the cell of origin of medulloblastoma—a malignant tumor in children that affects the central nervous system. In this study, scientists have used organoids to replicate the tumor tissue, for the first time.